Susan P. Perrine-Faller, MD

Professor, Pediatrics

Susan Perrine-Faller
617.638.5639
72 E. Concord St Instructional (L)

Other Positions

  • Professor, Hematology & Medical Oncology, Medicine, Boston University School of Medicine
  • Professor, Pharmacology & Experimental Therapeutics, Boston University School of Medicine
  • Research Faculty Member, Cancer Research Center, Boston University School of Medicine

Education

  • Tufts University School of Medicine, MD
  • Rutgers University–Camden, MMS
  • Harvard School of Public Health, SM
  • Mills College, BA

Publications

  • Published on 10/31/2016

    Faller DV, Castaneda SA, Zhou D, Vedamony M, Newburger PE, White GL, Kosanke S, Plett PA, Orschell CM, Boosalis MS, Perrine SP. An oral HemokineTM, a-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo. Blood Cells Mol Dis. 2017 Mar; 63:1-8. PMID: 27888688.

    Read at: PubMed
  • Published on 6/23/2016

    Whitesell PL, Owoyemi O, Oneal P, Nouraie M, Klings ES, Rock A, Mellman TA, Berihun T, Lavella J, Taylor RE, Perrine SP. Sleep-disordered breathing and nocturnal hypoxemia in young adults with sickle cell disease. Sleep Med. 2016 Jun; 22:47-49. PMID: 27544835.

    Read at: PubMed
  • Published on 12/29/2015

    Boosalis MS, Sangerman JI, White GL, Wolf RF, Shen L, Dai Y, White E, Makala LH, Li B, Pace BS, Nouraie M, Faller DV, Perrine SP. Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice. PLoS One. 2015; 10(12):e0144660. PMID: 26713848.

    Read at: PubMed
  • Published on 10/27/2015

    Dai Y, Sangerman J, Luo HY, Fucharoen S, Chui DH, Faller DV, Perrine SP. Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. Blood Cells Mol Dis. 2016 Jan; 56(1):62-9. PMID: 26603726.

    Read at: PubMed
  • Published on 4/1/2014

    Perrine SP, Pace BS, Faller DV. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. Hematol Oncol Clin North Am. 2014 Apr; 28(2):233-48. PMID: 24589264.

    Read at: PubMed
  • Published on 3/20/2014

    Patthamalai P, Fuchareon S, Chaneiam N, Ghalie RG, Chui DH, Boosalis MS, Perrine SP. A phase 2 trial of HQK-1001 in HbE-ß thalassemia demonstrates HbF induction and reduced anemia. Blood. 2014 Mar 20; 123(12):1956-7. PMID: 24652964.

    Read at: PubMed
  • Published on 11/13/2013

    Inati A, Kahale M, Perrine SP, Chui DH, Taher AT, Koussa S, Abi Nasr T, Abbas HA, Ghalie RG. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in ß-thalassaemia intermedia. Br J Haematol. 2014 Feb; 164(3):456-8. PMID: 24224649.

    Read at: PubMed
  • Published on 10/3/2013

    Kutlar A, Reid ME, Inati A, Taher AT, Abboud MR, El-Beshlawy A, Buchanan GR, Smith H, Ataga KI, Perrine SP, Ghalie RG. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013 Nov; 88(11):E255-60. PMID: 23828223.

    Read at: PubMed
  • Published on 3/27/2013

    Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, Taher A, Chaneim N, Boosalis M, Berenson R, Perrine SP. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in ß-thalassaemia intermedia and HbE/ß-thalassaemia. Br J Haematol. 2013 May; 161(4):587-93. PMID: 23530969.

    Read at: PubMed
  • Published on 8/7/2012

    Kutlar A, Ataga K, Reid M, Vichinsky EP, Neumayr L, Blair-Britt L, Labotka R, Glass J, Keefer JR, Wargin WA, Berenson R, Perrine SP. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2012 Nov; 87(11):1017-21. PMID: 22887019.

    Read at: PubMed

View 65 more publications: View full profile at BUMC

View all profiles